Cantor Fitzgerald Increases Earnings Estimates for Humacyte

Humacyte, Inc. (NASDAQ:HUMA - Free Report) - Analysts at Cantor Fitzgerald upped their FY2025 earnings estimates for shares of Humacyte in a research note issued on Wednesday, April 23rd. Cantor Fitzgerald analyst K. Kluska now forecasts that the company will post earnings of ($0.71) per share for the year, up from their previous forecast of ($0.95). The consensus estimate for Humacyte's current full-year earnings is ($1.27) per share.

Humacyte (NASDAQ:HUMA - Get Free Report) last issued its quarterly earnings results on Friday, March 28th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.23) by $0.07. The company had revenue of $7.23 million for the quarter, compared to analyst estimates of $0.64 million.

A number of other brokerages have also issued reports on HUMA. HC Wainwright restated a "buy" rating and set a $15.00 price target on shares of Humacyte in a research note on Wednesday, March 12th. D. Boral Capital restated a "buy" rating and set a $25.00 price target on shares of Humacyte in a research note on Wednesday, March 26th. Finally, Benchmark reiterated a "buy" rating on shares of Humacyte in a research note on Thursday, February 27th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $13.71.

Humacyte Price Performance

Humacyte stock traded down $0.02 during mid-day trading on Friday, reaching $1.41. 524,364 shares of the company traded hands, compared to its average volume of 3,570,815. Humacyte has a fifty-two week low of $1.15 and a fifty-two week high of $9.97. The company has a market capitalization of $218.16 million, a price-to-earnings ratio of -1.05 and a beta of 1.62. The firm's fifty day moving average is $2.27 and its two-hundred day moving average is $3.84.

Institutional Trading of Humacyte

Several hedge funds and other institutional investors have recently added to or reduced their stakes in HUMA. Barclays PLC grew its position in Humacyte by 177.6% during the third quarter. Barclays PLC now owns 236,742 shares of the company's stock valued at $1,288,000 after buying an additional 151,458 shares during the period. Geode Capital Management LLC grew its position in shares of Humacyte by 9.6% in the third quarter. Geode Capital Management LLC now owns 2,040,218 shares of the company's stock valued at $11,101,000 after purchasing an additional 179,120 shares during the period. Brookstone Capital Management acquired a new stake in shares of Humacyte in the fourth quarter valued at about $56,000. Clarus Wealth Advisors acquired a new stake in shares of Humacyte in the fourth quarter valued at about $207,000. Finally, ARS Investment Partners LLC grew its position in shares of Humacyte by 17.8% in the fourth quarter. ARS Investment Partners LLC now owns 99,419 shares of the company's stock valued at $502,000 after purchasing an additional 15,000 shares during the period. Institutional investors and hedge funds own 44.71% of the company's stock.

Insider Buying and Selling

In other news, CFO Dale A. Sander purchased 20,000 shares of the company's stock in a transaction that occurred on Thursday, April 10th. The shares were bought at an average price of $1.53 per share, for a total transaction of $30,600.00. Following the completion of the transaction, the chief financial officer now owns 40,600 shares in the company, valued at $62,118. This represents a 97.09 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Kathleen Sebelius purchased 50,000 shares of the company's stock in a transaction that occurred on Tuesday, April 8th. The shares were purchased at an average price of $1.32 per share, for a total transaction of $66,000.00. Following the transaction, the director now owns 91,207 shares of the company's stock, valued at $120,393.24. This trade represents a 121.34 % increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders have bought 83,993 shares of company stock valued at $118,224. Corporate insiders own 11.20% of the company's stock.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.